1. Articles in category: Drug

    1-24 of 336 1 2 3 4 ... 12 13 14 »
    1. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

      Clin Cancer Res. 2018 Mar 07;:

      Authors: Nguyen F, Alferiev IS, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM

      Read Full Article
      Mentions: Nanoparticles
    2. Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma;   Relapsed Cancer;   Refractory Cancer;   Adult Solid Tumor;   Adult Lymphoma Interventions :   Drug: Pembrolizumab;   Drug: Decitabine;   Radiation: Hypofractionated Index Site Radiation Sponsor :   Children's Hospital Medical Center, Cincinnati Recruiting

      Read Full Article
    3. Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and other diseases, today announced that it received notification on Friday, February 23, 2018 that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to taurolidine for the treatment of neuroblastoma. Taurolidine is currently in preclinical development for neuroblastoma and is a key component in the Company's lead product, Neutrolin®, a novel anti-infective ...

      Read Full Article
      Mentions: Treatment
    4. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    5. MELK is a novel therapeutic target in high-risk neuroblastoma.

      MELK is a novel therapeutic target in high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2591-2602

      Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

      Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

      Read Full Article
      Mentions: MYCN
    6. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    7. FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      Oncotarget. 2017 Dec 15;8(66):109985-109999

      Authors: Lange I, Espinoza-Fuenzalida I, Ali MW, Serrano LE, Koomoa DT

      Abstract Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression.

      Read Full Article
    8. Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.

      Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.

      Biochem J. 2018 Jan 02;:

      Authors: Schultz CR, Geerts D, Mooney M, El-Khawaja R, Koster J, Bachmann AS

      Abstract The eukaryotic initiation factor 5A (eIF5A), which contributes to several crucial processes during protein translation, is the only protein that requires activation by a unique post-translational hypusine modification.

      Read Full Article
      Mentions: DFMO
    9. mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      ACS Appl Mater Interfaces. 2018 Jan 03;:

      Authors: Haimov E, Weitman H, Polani S, Schori H, Zitoun D, Shefi O

      Abstract Photodynamic Therapy (PDT) is a promising therapeutic modality for cancer. However, current protocols using bare drugs suffer from several limitations that impede its beneficial clinical effects. Here, we introduce a new approach for an efficient PDT treatment.

      Read Full Article
    10. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      The European Commission has...

      Read Full Article
    11. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      Read Full Article
    12. Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

      Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

      Theranostics. 2017;7(17):4099-4117

      Authors: Villasante A, Sakaguchi K, Kim J, Cheung NK, Nakayama M, Parsa H, Okano T, Shimizu T, Vunjak-Novakovic G

      Abstract Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG.

      Read Full Article
      Mentions: Treatment
    13. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    14. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    15. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Carcinogenesis. 2017 Aug 29;:

      Authors: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M

      Read Full Article
    16. A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      Cell Syst. 2017 Sep 27;5(3):161-162

      Authors: Arora M, Spencer SL

      Abstract Live-cell imaging demonstrates that a subset of neuroblastoma cells evades chemotherapy-induced death if they are in early G1 phase of the cell cycle at the time of drug treatment and have sufficiently high levels of MYCN.

      PMID: 28957649 [PubMed - in process]

      Read Full Article
    17. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    18. Patient-derived xenografts as preclinical neuroblastoma models.

      Patient-derived xenografts as preclinical neuroblastoma models.

      Cell Tissue Res. 2017 Sep 19;:

      Authors: Braekeveldt N, Bexell D

      Abstract The prognosis for children with high-risk neuroblastoma is often poor and survivors can suffer from severe side effects. Predictive preclinical models and novel therapeutic strategies for high-risk disease are therefore a clinical imperative.

      Read Full Article
      Mentions: Side Effects
    19. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    20. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    1-24 of 336 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles